Genome-wide association studies: a primer by Corvin, A. et al.
Genome-wide association studies: a primer
A. Corvin1, N. Craddock2 and P. F. Sullivan3*
1 Department of Psychiatry, Trinity College Dublin, Dublin, Ireland
2 Department of Psychological Medicine, School of Medicine, Cardiﬀ, UK
3 Department of Genetics, University of North Carolina at Chapel Hill, NC, USA
There have been nearly 400 genome-wide association studies (GWAS) published since 2005. The GWAS approach has
been exceptionally successful in identifying common genetic variants that predispose to a variety of complex human
diseases and biochemical and anthropometric traits. Although this approach is relatively new, there are many
excellent reviews of diﬀerent aspects of the GWAS method. Here, we provide a primer, an annotated overview of the
GWAS method with particular reference to psychiatric genetics. We dissect the GWAS methodology into its
components and provide a brief description with citations and links to reviews that cover the topic in detail.
Received 26 June 2009 ; Revised 22 September 2009 ; Accepted 22 September 2009 ; First published online 9 November 2009
Key words : Genome-wide association study, psychiatric genetics, review.
Overview
The ﬁrst genome-wide association study (GWAS, ‘ je¯’
wo˘s ’) of age-related macular degeneration appeared
in 2005 (Klein et al. 2005). Since then, nearly 400 GWAS
articles have been published in the National Human
Genome Research Institute (NHGRI) GWAS Catalog
(www.genome.gov/26525384, accessed 20 September
2009). The GWAS approach has been exceptionally
successful in identifying common genetic variants that
predispose to a variety of complex human diseases
and biochemical and anthropometric traits and was
named the ‘breakthrough’ of 2007 by the journal
Science. Indeed, the GWAS method has performed
beyond expectations.
Although the GWAS approach is relatively new,
many excellent reviews of various components of the
GWAS method have already been published. Indeed,
the GWAS review literature is of such singular quality
that another review would be redundant. Therefore,
instead of another review, our aim is to provide a
primer, an annotated overview of the entire approach
with particular reference to psychiatric genetics. Our
aim is dissemination of information about this meth-
odology in order for a motivated reader to become
more expert. We dissect the GWAS methodology into
its components and, for each component, provide a
brief description and citations and links to reviews
that cover the topic in detail (Table 1).
An introduction to GWAS methodology
Basic principles in genetics
It is beyond the scope of this review to cover funda-
mental topics in genetics, but some useful starting
points are shown in Table 1.
Deﬁnition
A GWAS for a disease is usually a variant of a cross-
sectional case-control study, the study design that is
the familiar workhorse in biomedicine and epidemi-
ology (Schlesselman, 1982). Another term for GWAS is
whole-genome association study (WGAS, ‘du˘b’ @l-yo¯o¯
ga˘s ’). Cases are deﬁned as individuals who meet life-
time criteria for a disease, for example Crohn’s
disease, type 2 diabetes mellitus (T2DM), or schizo-
phrenia. Controls should have never met criteria for
the disease and, ideally, be through the period of risk.
Moreover, for case-control comparisons to be as un-
biased as possible, controls should be drawn from the
same population as cases, particularly with respect to
exposure to any potentially relevant risk factors
(Rothman, 1986). Each individual in the sample is as-
sayed (i.e. genotyped) for a comprehensive set of
genetic markers scattered across the genome. The
genetic markers are single nucleotide polymorphisms
(SNPs, ‘snips ’), which are relatively straightforward
to assay. The two major current GWAS technological
platforms contain 906000 (Aﬀymetrix 6.0) and 1199187
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Table 1. Further primer information by topic
Topic Citation Comment Link
Genetics fundamentals – NHGRI glossary of genetic terms www.genome.gov/10002096
– NHGRI genetics education resources www.genome.gov/10000464
– Genetics fundamentals, from Nature www.nature.com/nrg/series/fundamental/index.html
Strachan & Read, 2003 Introduction to genetics and human genetics www.garlandscience.co.uk/textbooks/0815341822.asp
Nussbaum et al. 2007 Medical genetics introductory text www.elsevier.com/wps/ﬁnd/bookdescription.
cws_home/711519/description#description
Attia et al. 2009 a Brief introduction to key concepts www.ncbi.nlm.nih.gov/pubmed/19126812
GWAS basics Hardy & Singleton, 2009 Excellent GWAS review www.ncbi.nlm.nih.gov/pubmed/19369657
McCarthy et al. 2008 Excellent GWAS review www.ncbi.nlm.nih.gov/pubmed/18398418
<unpublished> NHGRI GWAS catalog, frequently updated www.genome.gov/GWAStudies
Chanock et al. 2007 Standards for replication in GWAS www.ncbi.nlm.nih.gov/pubmed/17554299
Barrett et al. 2008 Meta-analysis example (Crohn’s disease) www.ncbi.nlm.nih.gov/pubmed/18587394
Psychiatric – PGC web site http://pgc.unc.edu
GWAS PGC, 2009 a Provides a framework for interpreting PGC ﬁndings www.ncbi.nlm.nih.gov/pubmed/19002139
Consortium PGC, 2009 b Describes history and rationale of PGC www.ncbi.nlm.nih.gov/pubmed/19339359
Phenotypic issues Craddock et al. 2007 Phenotypic complexity within psychoses www.ncbi.nlm.nih.gov/pubmed/17329738
PGC Cross Disorder Group, 2009 Describes PGC approaches to phenotypic complexities www.ncbi.nlm.nih.gov/pubmed/19648536
Kendler, 2006 Review of issues in phenotypic deﬁnitions for genetics www.ncbi.nlm.nih.gov/pubmed/16816216
Schulze & McMahon, 2004 Empirical approaches to phenotypic complexity www.ncbi.nlm.nih.gov/pubmed/15812169
Genotyping – Description of current Aﬀymetrix GWAS platform www.aﬀymetrix.com/products_services/arrays/
speciﬁc/genome_wide_snp6/genome_wide_snp_6.aﬀx
– Description of current Illumina GWAS platform www.illumina.com/pages.ilmn?ID=335
Scherer et al. 2007 Copy number variation, background www.ncbi.nlm.nih.gov/pubmed/17597783
Cook & Scherer, 2008 Copy number variation in neuropsychiatry www.ncbi.nlm.nih.gov/pubmed/18923514
GWAS quality control McCarthy et al. 2008 Excellent GWAS review, including QC steps www.ncbi.nlm.nih.gov/pubmed/18398418
WTCCC, 2007 Superb example of GWAS QC in practice www.ncbi.nlm.nih.gov/pubmed/17554300
Neale & Purcell, 2008 Review of GWAS QC www.ncbi.nlm.nih.gov/pubmed/18500721
Attia et al. 2009 b Assessing the validity of a GWAS www.ncbi.nlm.nih.gov/pubmed/19141767
Bioinformatics Konneker et al. 2008 SLEP, web search engine for psychiatric genomics http://slep.unc.edu
Allen et al. 2008 SZGene, genetic studies of schizophrenia www.schizophreniaforum.org/res/sczgene
Pathway analysis Hong et al. 2009 Comparison of pathway analysis methods www.ncbi.nlm.nih.gov/pubmed/19408013
Holmans et al. 2009 Description of one method (ALIGATOR) www.ncbi.nlm.nih.gov/pubmed/19539887
Meta-analysis de Bakker et al. 2008 GWAS meta-analysis www.ncbi.nlm.nih.gov/pubmed/18852200
Follow-up Ioannidis et al. 2009 Follow-up of GWAS ﬁndings www.ncbi.nlm.nih.gov/pubmed/19373277
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SNPs (Illumina 1M) spaced across the 22 autosomes
(chr1–chr22), the sex chromosomes (chrX and chrY)
and the mitochondrial genome (chrM).
The key analysis in a GWAS for a disease is logistic
regression with the dependent variable case-control
status (1=case, 0=control) and a SNP genotype as an
independent variable [coded as the number of copies
of the minor or less frequent allele, 1 degree of free-
dom (df)]. The output of a logistic regression is ident-
ity of the reference allele and an odds ratio with its
standard error (or conﬁdence intervals) along with a
statistic and a p value that tests whether the odds ratio
diﬀers from unity.
Standard of evidence
In a GWAS, logistic regressions are done for every
SNP (i.e. a total of y1 million regression models).
Given the number of statistical tests, p values that are
very small by traditional standards are to be expected
merely by the play of chance (e.g. 10 p values
<0.00001 and 100 p values <0.0001). Thus, the stan-
dard of evidence that has emerged for a compelling
GWAS ﬁnding is rigorous : (a) a strong association in
an initial sample, (b) precise replication in one or more
independent samples (i.e. the same SNP, allele, and
direction of association), and (c) a cumulative p value
<5r10x8 (Chanock et al. 2007). The 5r10x8 threshold
is akin to a Bonferroni correction of the traditional 0.05
Type 1 error level for 1 000 000 statistical tests (although
the full argument is more complex as some of these
tests are not independent because of linkage dis-
equilibrium) (Pe’er et al. 2008). p values that are smaller
than expected by chance and that replicatewell in other
samples highlight a genomic region associated with a
disorder (and potentially causal).
Statistical power
Because of the requirement to adjust for the large
number of statistical tests to control Type 1 error, ad-
equate statistical power (to minimize Type 2 error) is
crucial, particularly given the small genetic eﬀect sizes
typical for human GWAS ﬁndings (discussed later).
Fig. 1 shows power curves for four diﬀerent sample
sizes. Given the large number of statistical tests and
because the genetic eﬀects are likely to be subtle,
power is inadequate unless very large numbers of
cases and controls are studied.
GWAS statistics
We illustrate here some properties of published
GWAS in biomedicine from the NHGRI GWAS
Catalog (accessed 20 September 2009). Of 396 pub-
lished GWAS, there were 238 studies reporting 693G
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SNP associations with p<5r10x8. These associations
were for 59 human diseases and 61 other quantitative
traits. The diseases with the greatest number of associ-
ations were Crohn’s disease, T1DM, T2DM, prostate
cancer, and rheumatoid arthritis. The top quantitative
traits were height, lipid levels [triglycerides, high
density lipoprotein (HDL) and low density lipoprotein
(LDL) cholesterol], QT interval, and body mass index.
Fig. 2 a shows the temporal trends in the publication
dates for these studies. Fig. 2 b illustrates some of the
properties of the ﬁndings from the literature. Note that
only about 15% of the SNP–disease associations are
detectible with 90% power, with a sample of 1000
cases and 1000 controls, whereas only about 4%would
not be detected with 25 000 cases and 25 000 controls
(the estimated number of GWAS samples available for
schizophrenia and bipolar disorder by 2014). This is
an important point : based on power calculations and
empirical ﬁndings for other disorders, ‘ failure ’ to de-
tect an association is meaningful only if the sample
size is very large.
Several intriguing trends were evident in these data
on human diseases. First, with few exceptions [e.g.
Alzheimer’s disease and the apolipoprotein E gene
(APOE)], the regions implicated by GWAS were not
previously known. Candidate genes based on prior
knowledge of pathophysiology or intuition have
usually not been identiﬁed. Second, the majority of
these ﬁndings (90%) were not in the coding region of a
gene, and only 8% were non-synonymous variants
(i.e. DNA variants that change the amino acid se-
quence of the corresponding protein). Indeed, 43%
were not in a known gene and 23% were not within
20 000 bases of a known gene. Common variation
underlying complex human diseases is dissimilar to
that underlying Mendelian diseases where major
changes to proteins are typical.
Meta-analysis
Given the requirement for historically large sample
sizes, it has become typical for primary studies to band
together to form meta-analytic consortia. This has
proven to be a crucial step in achieving suﬃcient
statistical power. For example, two primary T2DM
GWAS were unremarkable individually and yet, after
meta-analysis, multiple highly signiﬁcant and rep-
licated ﬁndings emerged (Saxena et al. 2007 ; Scott et al.
2007).
GWAS for psychiatric disorders
Multiple GWAS for psychiatric disorders have been
published, are in progress, or are planned. The dis-
orders include anorexia nervosa, attention deﬁcit
hyperactivity disorder (ADHD), autism, bipolar dis-
order, drug use disorders (smoking behavior and
alcohol dependence), major depressive disorder,
obsessive–compulsive disorder, and schizophrenia.
There are more than 50 primary samples, mostly in
subjects of European ancestry but with increasing
numbers of subjects of African and East Asian ances-
try. Prominent examples of GWAS ﬁndings for psy-
chiatric disorders are described in Table 2. This area is
expanding rapidly, and additional ﬁndings are known
to be in the publication pipeline.
The Psychiatric GWAS Consortium (PGC) was
formed in 2007 to conduct a ‘mega-analysis ’ of indi-
vidual genotype and phenotype data, and is described
in detail elsewhere (Cross-Disorder Phenotype Group
of the Psychiatric GWAS Consortium, 2009; Psy-
chiatric GWAS Consortium, 2009 a, b). GWAS data for
ADHD, autism, bipolar disorder, major depressive
disorder and schizophrenia from European subjects
are being analyzed as of this writing in September
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Fig. 1. Statistical power in a genome-wide association study (GWAS) for four diﬀerent sample sizes assuming a discrete trait
with lifetime prevalence of 0.01 (similar to schizophrenia, bipolar disorder or anorexia nervosa), a log additive genetic model,
and a genotypic relative risk of 1.25 (typical for GWAS for human complex diseases), and two-tailed a=5r10x8. The x axis
shows minor allele frequency and the y axis statistical power.
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2009. To our knowledge, this study of >59 000 inde-
pendent cases and controls and >7700 family trios
will be the largest biological experiment conducted in
psychiatry.
The PGC has two major aims. The ﬁrst is to conduct
ﬁve separate GWASmega-analyses forADHD, autism,
bipolar disorder, major depressive disorder, and
schizophrenia. The second comprises cross-disorder
mega-analyses with two components. The ‘nosologi-
cal ’ subaim takes cases as deﬁned by DSM-IV criteria
and looks for SNPs that are compellingly associated
with two or more disorders and eﬀectively searches
for genomic regions with pleomorphic eﬀects. The
‘heterogeneity ’ subaim reclassiﬁes subjects according
to prespeciﬁed phenotypic characteristics (e.g. subjects
with bipolar disorder with two manic episodes and
many depressive episodes should be more major de-
pression-like than bipolar-like). This is a convenient
segue to the next issue: are psychiatric phenotypes
qualitatively diﬀerent from other biomedical diseases?
Genetic models
One of the major unknowns for psychiatric disorders
is the nature of the genetic models by which variation
at the DNA level increases risk for the clinical pheno-
type. For Mendelian disorders, a genetic model can be
hypothesized by examination of pedigrees (e.g. domi-
nant, recessive or sex-linked) and knowledge of preva-
lence. For psychiatric diseases, we assume complex
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Fig. 2. Properties of genome-wide association study (GWAS) ﬁndings from the literature. (a) Quarterly temporal trends in
the publication of GWAS. (b) The accumulated GWAS literature on human diseases. The x axis is the population prevalence
of a risk variant and the y axis the relative risk conferred (both using a log10 scale to provide separation). The gray points
show the prevalence–risk combination for all single nucleotide polymorphism (SNP) associations for human complex
diseases with p<5r10x8. Power curves are shown for 1000 cases/1000 controls (red line) and 25 000 cases/25 000
controls (green line). The blue lines depict the 10th–90th percentiles from the GWAS literature for allele frequency (horizontal
line) and relative risk (vertical line). The intersection of the blue lines is the median population prevalence (0.3) and relative
risk (1.25).
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inheritance (allowing for mixtures of genetic and
environmental eﬀects along with diagnostic im-
precision). Two genetic models have received par-
ticular attention : that complex traits are caused by
common versus rare genetic variation. In the former,
psychiatric disease results from the cumulative eﬀect
of many genetic variants, each of which is common in
the population and confers subtle genetic risk [the
common disease/common variant model (CDCV)]. In
the latter, psychiatric disease results from many dif-
ferent mutations, each of which is rare but of powerful
eﬀect [the multiple rare variant model (MRV)].
Some commentators hold extremist views, for
example that psychiatric diseases arise only from an
MRV model (see the Controversies section below).
However, empirical results to date are consistent with
a place for both MRV and CDCV models. For schizo-
phrenia, bipolar disorder and autism, the data are
consistent with the presence of multiple common vari-
ants of subtle eﬀect in some patients and rare variants
in others. More examples are likely to emerge with
improved technologies and larger sample sizes.
One fascinating empirical development has been
the emergence of the ‘proﬁle score ’ concept, an ex-
treme form of the CDCV model. In a recent Nature
paper (International Schizophrenia Consortium, 2009),
the authors developed a list of approximately 30 000
SNPs and their risk alleles in one large schizophrenia
case-control sample. This list can be used to compute a
risk proﬁle for each person in independent samples
(i.e. the number of schizophrenia risk alleles). The
score from the initial sample signiﬁcantly predicted
schizophrenia risk in three independent samples
(p values 2r10x28, 5r10x11, and 0.008), bipolar risk
in two independent samples (p values 1r10x12 and
9r10x9), and, importantly, was not associated with
risk of six non-psychiatric biomedical disorders
(Crohn’s disease, T1DM, T2DM, coronary artery dis-
ease, hypertension and rheumatoid arthritis). These
data strongly support the CDCV model and also
suggest genetic overlap between schizophrenia and
bipolar disorder.
From these basic models, multiple elaborations are
possible. For example, diﬀerent genetic variants in
the same gene could be associated with a disease in
diﬀerent populations.
As an example of MRV, copy number variation
(CNV) has emerged as a rare but powerful risk factor
for neuropsychiatric disorders. CNVs are segments
of the genome >1000 bases where the number of
copies of this segment is diﬀerent from the expected
number. Down’s syndrome is an example where three
copies (instead of two) of chr21 are present. The
chr22q11 hemi-deletion (one copy of chr22 from
17.3–20.3 million bases) is another example, and has
been associated with multiple neuropsychiatric dis-
orders. GWAS chips also contain many CNV probes,
leading to increasing interest in this topic.
The phenotype
The most important issue in a case-control study is
how to deﬁne cases and controls, and this is particu-
larly so in psychiatric genetics. This is more diﬃcult
to deﬁne and measure than for most non-psychiatric
disorders. Furthermore, we have less knowledge of
the causes and mechanisms of pathogenesis. Our
current oﬃcial classiﬁcation systems, DSM and ICD,
are descriptive systems that were developed to have
clinical utility and acceptable reliability, but with no
expectation that the categories represented valid en-
tities with respect to etiology. Although these pheno-
type deﬁnitions are moderately to highly heritable and
hence sensible starting points for genetic research, it
is generally agreed that the most useful biological
categories and/or dimensional deﬁnitions and
measures are still unknown. The strikingly high level
of co-occurrence of diﬀerent diagnoses within the
same individual (‘co-morbidity ’) almost certainly re-
ﬂects a substantial overlap in the underlying biology
Table 2. Notable psychiatric GWAS ﬁndings (as of September 2009)
Disease Citation Locus Subjects
MAF
(OR)a Best SNP and p value
Autism Wang et al. 2009 CDH10-CDH9 intergenic 12 834 0.38 (1.19) rs4307059, 2r10x10
Bipolar disorder Ferreira et al. 2008 ANK3 10 596 0.05 (1.45) rs10994336, 9r10x9
CACNA1C 10 596 0.32 (1.18) rs1006737, 7r10x8
Schizophrenia O’Donovan et al. 2008 ;
International Schizophrenia
Consortium, 2009 ; Shi et al. 2009 ;
Stefansson et al. 2009
MHC-NOTCH4 region 47 536 0.85 (1.15) rs3131296, 2r10x10
MHC-histone cluster 47 536 0.87 (1.19) rs6913660, 1r10x9
NRGN 47 536 0.83 (1.15) rs12807809, 2r10x9
TCF4 47 536 0.06 (1.23) rs9960767, 4r10x9
ZNF804A 20 142 0.59 (1.12) rs1344706, 2r10x7
a Illustrative minor allele frequency (MAF) in controls and odds ratio (OR).
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of currently deﬁned syndromes. This is further
evidenced by family studies demonstrating shared
familial liability across diagnostic boundaries (e.g.
schizophrenia and bipolar disorder) (Lichtenstein et al.
2009). It is interesting to note that some of the strongest
association signals to emerge from GWAS of schizo-
phrenia and bipolar disorder show an overlap across
traditional disorder categories (International Schizo-
phrenia Consortium, 2009).
In view of these observations, it can be expected that
a range of approaches to the clinical phenotype may be
required to maximize the potential from molecular
genetic studies. This includes analyses across the tra-
ditional illness categories (‘ lumping’) and analyses of
clinically meaningful subsets within a category or set
of categories (‘splitting’). It is also possible to use ap-
proaches that are not based on any speciﬁc prior
model of the clinical phenotype and to seek clinical
entities (whether they are categories or dimensions)
that would ‘make more sense’ from a genetic perspec-
tive. For example, for a highly signiﬁcant and consist-
ently replicated genetic association, cases with and
without the genetic variant can be investigated in an to
attempt to identify the phenotypic consequences of the
variant : do cases with the variant have earlier onset,
more severe symptoms, worse response to treatment,
or alter brain structure or function? This is also know
as ‘reverse phenotyping’ or ‘phenotype reﬁnement ’.
Another analytic possibility, which will be particularly
valuable if there is a high degree of polygenicity (i.e.
hundreds or thousands of susceptibility alleles of
small eﬀect), will be to consider a large set of polymor-
phisms and use aggregate measures of their overall
contribution to phenotypic susceptibility to seek to
deﬁne ‘signatures ’ of genetic variants, the patterns of
which could be compared across phenotypes.
Molecular genetics will certainly not provide a
simple, gene-based classiﬁcation of psychiatric illness.
However, it can be expected that establishing the
relationship between genotypes and psychiatric
phenotypes will inform understanding of psychiatric
nosology and move psychiatry towards a diagnostic
classiﬁcation that is much closer to the underlying
pathophysiology than are the current descriptive
classiﬁcations. This may well be a relatively early and
clinically important ‘pay-oﬀ’ from the major research
investment in molecular genetic research in psy-
chiatry.
GWAS genotyping
Source of DNA
DNA samples are readily obtainable from multiple
sites although most studies use peripheral blood
lymphocytes from venous samples. Some studies use
samples from the oral cavity (buccal scrapings or epi-
thelial cells in saliva) but these samples can be plagued
by smaller DNA quantity, inferior DNA quality, and
interference of DNA from oral microbial ﬂora. Some
samples are derived from lymphocytes transformed
by Epstein–Barr virus into immortalized cell lines but
such samples can have artifacts that complicate some
analyses (e.g. trisomy 12 in copy number analyses).
Although some investigators advocate using DNA
pooling due to lower cost (i.e. genotyping aggregated
cases and aggregated controls), this approach can have
serious issues with accuracy and reliability and has
not entered wide usage.
Genotyping
The cost of genotyping has decreased by a factor of
2000 in the past decade with the development of
reliable, robust and highly multiplexed genotyping
systems (meaning that many genetic markers are
genotyped simultaneously) and because of compe-
tition between multiple companies. As of this writing
in mid-2009, Aﬀymetrix and Illumina are the main
suppliers of GWAS genotyping platforms. Each uses
diﬀerent technologies and each has advantages and
disadvantages in regard to genotyping accuracy,
genomic coverage, ease of use, and total cost. Both
platforms genotype a predeﬁned set of SNPs, an
important reason why cost has decreased. SNPs are
genotyped as they are relatively common in the
human genome and relatively straightforward to
assay.
For each platform, genotyping takes 3 or 4 days
per sample, and most laboratories run tens or even
hundreds of samples simultaneously. Such high
throughput means that even large-scale projects can
be completed in under a year. In practice, there are
always numerous issues to resolve, such as subjects
whose stated sex does not match patterns of chrX
and chrY SNPs or samples that are unexpectedly
identical.
Genotype calling
For each SNP, GWAS platforms assess each of the two
possible alleles with independent assays that can be
viewed as a scatter plot. Fig. 3 a depicts a scatter plots
for two SNPs in a GWAS. The scatter plots show the
intensity values for one SNP allele plotted by the in-
tensity values for the other SNP allele with each point
corresponding to one subject. In the scatter plot on the
left of Fig. 3 a, the points fall into three well-deﬁned
clusters, and individuals in each cluster are ‘called’ as
having the same genotype for that SNP (i.e. GG, AG or
GWAS primer 1069
AA). A genotype calling algorithm is used to assign
these clusters into genotypes for each subject. The
scatter plot on the right shows an example of poor
cluster separation, and this SNP should be excluded
from analysis.
GWAS analysis
Quality control (QC)
One of the most important and time-consuming steps
in conducting a GWAS is QC, the removal of SNPs and
subjects with unreliable data plus assessment of biases
that might lead to spurious results. Excellent reviews
of GWAS QC are available (McCarthy et al. 2008 ;
Neale & Purcell, 2008 ; Attia et al. 2009 b).
Individual SNPs are removed for any of the fol-
lowing reasons :
 Imprecise mapping to the genome (some SNPs map
to multiple places).
 Excessive disagreement among duplicated samples.
 Excessive missing genotypes on subjects (e.g.>5%).
 Low minor allele frequency (e.g.<1%).
 Observed genotype frequencies deviate markedly
from expectations (e.g. Hardy–Weinberg equilib-
rium p<1r10x6).
After SNP removal, subjects are dropped for any of
the following:
 Disagreement between chrX/chrY genotypes and
phenotypic sex (usually indicating an unreliable
link between genotype and phenotype data).
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Fig. 3. Images important for assessing a genome-wide association study (GWAS). These ﬁgures are from diﬀerent studies.
(a) The allele intensity plots for two single nucleotide polymorphisms (SNPs) from which SNP genotype calls are generated.
(b) A quantile–quantile plot in which the observed p values are plotted against the p value distribution expected by chance
(onxlog10 scale). (c) A Manhattan plot. (d) An expanded set of ﬁndings in the region of neuregulin 1 (NRG1). See text
for more detailed description.
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 Excessive missing data (e.g.>5%).
 Inadvertent sample duplication or close relation
(monozygotic twin or ﬁrst- or second-degree rela-
tive) to some other subject.
 Ancestry outlier.
Bias
As there are hundreds of thousands of SNPs per sub-
ject, relatives are readily identiﬁed and excluded as
their presence can lead to inﬂation of Type 1 error.
Similarly, genome-wide data allow identiﬁcation and
control for the most infamous bias of a case-control
study, inﬂation of Type 1 error due to population
stratiﬁcation. This occurs when cases and controls
are mismatched by ancestry and disease prevalence
diﬀers by ancestry, and has been responsible for
numerous false-positive ﬁndings in the literature.
With genome-wide SNP data, it is possible to identify
individuals with divergent ancestry (even within
a continental population) ; these individuals can be
excluded or a statistical method used to control for this
bias.
In addition, important bias can be introduced if
samples from cases and controls are handled diﬀer-
ently ; for example if samples from cases are older, if
DNA has been extracted with a diﬀerent method from
controls, or if cases are genotyped at a diﬀerent place
and time from controls. Careful assessment of these
and other sources of bias is crucial to understanding
the impact of a range of method artifacts.
Statistical testing
Using the SNPs and subjects that passed QC, in-
vestigators generally use logistic regression with case-
control status as the dependent variable and a single
SNP as the predictor. The SNP is coded as 0, 1 or 2
(i.e. the number of copies of one of the two alleles) for
an additive test with 1 df. This analysis is repeated
for each SNP for a million or more statistical tests.
Some investigators include covariates in the logistic
regression model such as age, sex or indicators of an-
cestry. In some instances, alternative genetic models
are used (e.g. recessive or dominant) but most studies
use a 1 df additive test as the primary statistical test.
Multiple testing
A typical GWAS for one disease includes one logistic
regression per SNP, or at least 500 000 statistical tests.
These tests are not all independent as SNPs that are
located close to one another can be correlated because
of linkage disequilibrium. Even so, with 105–106 stat-
istical tests, very small p values by conventional stan-
dards are expected by chance. As noted earlier, p
values <5r10x8 (akin to a Bonferroni correction of
the traditional 0.05 Type 1 error level for 1 000 000
statistical tests) (Pe’er et al. 2008) are generally re-
quired for signiﬁcance. Experience suggests that ﬁnd-
ings more signiﬁcant than this threshold tend to
replicate well across studies. However, unless power
is exceptional, it is generally incorrect to exclude a
SNP from consideration if does not exceed this
threshold. Indeed, some SNPs that are unimpressive
in an initial study (e.g. p=0.001) can eventually repli-
cate well and exceed the critical threshold. As em-
phasized above, replication is essential.
Visualization
The scale of a GWAS can be overwhelming, and many
ﬁnd it helpful to use graphics to depict certain results.
Fig. 3 b shows a quantile–quantile plot, a scatter plot of
the p values observed in a GWAS versus that expected
by chance. To spread the graph out, the points are
transformed usingxlog10(p value) (e.g. 0.0001 or 10x4
becomes +4.0). In this instance, the plot shows that
the observed p values conform closely to the expected,
suggesting that no ﬁnding is individually impressive
after accounting for multiple comparisons. Fig. 3 c
shows a ‘Manhattan plot ’ (to some eyes, this re-
sembles the night skyline of the Manhattan borough of
New York City viewed from across the Hudson River),
a depiction of all small p values by genomic position.
These results (from a diﬀerent study than in Fig. 3 b)
suggest that genomic regions on chromosomes 4, 6, 7,
10 and 12 exceed genome-wide signiﬁcance. Fig. 3 d
(again from a diﬀerent study) shows an expanded
view of a genomic region of interest [neuregulin 1
(NRG1)]. The region of maximum signal on the right-
hand side of the graph is quite far from the region
suggested as a risk factor for schizophrenia (on the far
left-hand side of the ﬁgure).
Imputation
Samples from the HapMap project have been geno-
typed for a very large number of SNPs. Under the
assumption that these samples (e.g. the northern
European subset) are comparable to members of a
case-control collection, the combination of these data-
sets can be used to estimate (impute) genotypes in the
case-control collection by treating it as a missing data
problem. Thus, it is possible to increase the number of
available genotypes from, for example, 500 000 di-
rectly assessed SNPs to 2 million directly genotyped
and imputed SNPs. A major use of imputation is to
allow direct comparison of case-control studies that
were genotyped using diﬀerent GWAS platforms. For
GWAS primer 1071
many of the Aﬀymetrix and Illumina platforms, the
number of SNPs directly genotyped on both platforms
is <20%. Imputation is often an essential precursor
for meta-analysis.
Bioinformatics
Two web resources for investigating psychiatric gen-
etics ﬁndings are shown in Table 1 (Allen et al. 2008 ;
Konneker et al. 2008). GWAS analyses described above
take an agnostic approach to GWAS data. Experience
gleaned from other diseases indicates that SNPs
identiﬁed and conﬁrmed by replication are not
necessarily those with the smallest p values in an in-
itial study. Bioinformatics approaches can be useful
in annotating and organizing GWAS SNP data to
identify SNPs for replication. SNPs may be prioritized
based on many additional types of information : pre-
vious genetic association data ; by location in exons,
putative functional regions of the genome, or in brain-
expressed genes ; or on the basis that the identiﬁed
SNP allele has an eﬀect on gene expression in brain
(Xu & Taylor, 2009).
Pathway analysis
Pathway analysis represents an alternative analytical
approach to interrogating GWAS data. Several formal
pathway-based analytical methods have been de-
scribed (Hong et al. 2009). Essentially, these methods
attempt to establish whether SNPs mapping to genes
in a pathway show more evidence of association with
a disorder than other SNPs in the GWAS, or SNPs
mapping to other pathways. Pathway refers to groups
of genes that are similar in some way, for example
highly expressed in a tissue such as prefrontal cortex,
or crucial to a biological process such as neuronal dif-
ferentiation. The approach can be applied to test for
involvement of speciﬁc pathways, to perform a hy-
pothesis-free test of many diﬀerent pathways, or to
investigate whether pre-identiﬁed risk genes may be
involved in the same molecular pathway or process.
Investigating at the level of molecular pathways rather
than individual risk variants may oﬀer several poten-
tial advantages by being robust to the eﬀects of genetic
heterogeneity or in reducing the total multiple testing
burden in analysis. However, this approach is depen-
dent on the quality of annotation of the pathways be-
ing investigated (which can be uncertain) and assumes
that risk variation falls within genes. As mentioned in
our description of GWAS for human diseases, a large
subset of identiﬁed genetic risk variation (43%) fell
outside gene boundaries. Arguably the principal
advantage of this approach is to establish additional
information relating to function over and above the
statistical SNP GWAS data. Implicating a molecular
pathway in a disease process is likely to be more
biologically informative than interpreting evidence
of involvement of an anonymous genetic marker.
Meta-analysis
Conducting a meta-analysis, the combined analysis of
summary results from multiple primary studies, is
now known to be crucial in the identiﬁcation of robust
genetic signals. This general principle has been ident-
iﬁed on multiple occasions, as evidenced by studies of
Crohn’s disease, T1DM and T2DM (Barrett et al. 2008,
2009 ; Zeggini et al. 2008). As discussed earlier, the
PGC is conducting such analyses for psychiatric dis-
orders.
However, a high-quality meta-analysis must con-
front and surmount numerous conceptual and tech-
nical issues. These issues include : the comparability of
samples and phenotype deﬁnitions ; quality control ;
imputation to a common genotype set with attention
to strand and allele issues ; statistical methods to
combine data ; visualization; bioinformatics ; and fol-
low-up strategies. de Bakker et al. (2008) provide a
practical treatment of these issues.
Follow-up strategies
Assuming that a GWAS identiﬁes a highly re-
producible and consistently replicated association
with a genomic region : what next? The implications
are discussed in the next section (ELSI) and additional
follow-up experiments are described here (Ioannidis
et al. 2009). The fundamental idea is to design exper-
iments to develop a detailed understanding of how
changes at the genetic level act and interact with the
environment to alter risk of a psychiatric disorder.
These experiments should be at multiple levels : DNA,
RNA, protein, biological process, cell, local cell sys-
tems, organ, organ system, organism, and community
levels are all potentially relevant.
These associations could be direct (i.e. the identiﬁed
variant is the causal variant) but are more likely to be
associated indirectly in that the identiﬁed variant is
correlated with some other genomic variant. For in-
direct association, the causal variant could be some
other SNP, a set of interacting SNPs, a haplotype, an
insertion/deletion polymorphism, a CNV, or a more
complex type of genetic variant. It is also wise to leave
open the possibility of a causal genetic mechanism that
is currently unknown. The genetic eﬀects are highly
likely to be subtle and probabilistic (and even con-
ditionally dependent on external inﬂuences) rather
than deterministic as with classical Mendelian dis-
orders.
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DNA
Broadly, genetic follow-up aims to validate and reﬁne
notable SNP associations to identify underlying causal
variants and map their relationship to clinical pheno-
types. One approach, beyond simple replication, is to
investigate an implicated genomic region at higher
marker density to reﬁne the association signal (ﬁne-
mapping). For other complex diseases this approach
has met with mixed results, suggesting that in many
cases the impact of risk variants on common disease
phenotypes is complex and not necessarily related to
obvious eﬀects on gene function, such as alteration of
protein structure. This may relate to the limited
coverage achieved by these studies, but it has been
estimated that by direct genotyping and imputation a
large percentage (>85%) of common SNP variation is
already being assayed by GWAS, although this can
vary markedly by genomic region.
Many investigators would conduct regional ‘deep’
resequencing of large numbers of cases and controls to
discover previously unknown genetic variants. The
emerging technology of genome resequencing has
shown that there is usually an array of undiscovered
genetic variants. A more detailed understanding of
genetic variation in human populations will soon be
available through the 1000 Genomes Project
(www.1000genomes.org), which is performing geno-
mic resequencing of >1000 people from around the
world. This is likely to prove very informative in
guiding ﬁne-mapping studies and potentially un-
tangling more complex eﬀects on phenotype.
Alternative genetic mechanisms may also contrib-
ute to disease, and disruption of the same genes or
molecular pathways by diﬀerent mechanisms is likely
to be relevant to the consequent phenotype. Follow-up
strategies are increasingly using GWAS results to test
other genetic risk mechanisms such as involvement of
CNV, the cumulative impact of CNV burden (e.g. the
number of CNVs), and the cumulative impact of hun-
dreds or thousands of SNP genotypes. In addition,
investigators are actively working to assess the
cumulative impact of individually rare risk alleles and
epigenetic phenomena such as methylation.
RNA
A potentially useful gene annotation is whether a
genetic variant leads to changes in RNA abundance or
structure. This so-called quantitative trait loci (QTL)
approach is in its early stages, but reﬁnement and
larger studies could give investigators a useful set of
initial hypotheses should an associated region be
shown to alter messenger RNA for a nearby gene.
These data can also be used to answer the question : to
what gene does an associated SNP ‘belong’?
Investigators usually assume that a SNP exerts its im-
mediate eﬀect on a gene it is in or near. In general, this
assumption may be reasonable, but there are examples
where this assumption is incorrect (e.g. lactase per-
sistence is due to MCM6 intronic variation, y14 kb
from the lactase gene). Moreover, 23% of GWAS hits
are >20 kb from known genes. Fascinating examples
include the 8q24 ‘gene desert ’ (30–500 kb from MYC)
that is robustly associated with multiple diﬀerent
cancers and a 5p14 region with replicated associations
with autism buty1 Mb from the nearest gene.
Molecular and cellular biology
There are many powerful technologies that could be
brought to bear. These approaches are too numerous
to describe succinctly and their choice depends on the
details of a genomic variant. In many instances, use of
transgenic manipulation (knock-out or humanizing
knock-in approaches) of non-human model organisms
(mouse or worm in particular) might be used to gain
greater understanding of the impact of a genomic
variant.
Clinical
Risk variants identiﬁed by GWAS are individually
likely to be of modest eﬀect, which poses challenges
for clinical follow-up studies. These are not insur-
mountable, but are at present dependent on the avail-
ability of detailed phenotypic information from
subjects involved in GWAS or the ability to recontact
subjects for additional studies. Recent eﬀorts in schizo-
phrenia demonstrate the application of a phenotype
reﬁnement approach, in this case identifying a dis-
turbed neural connectivity phenotype in carriers of the
risk allele at ZNF804A using a neuroimaging approach
(Esslinger et al. 2009). If disorders are highly polygenic
it might be possible to group participants into classes
based on total burden of risk variation or contribution
from diﬀerent functional pathways. Such groupings
could than be used within a disorder, or across current
diagnostic boundaries, to investigate clinical proﬁles,
cognitive functioning, drug response or clinical out-
come. By extension, such approaches could also be
applied to investigate gene–environment interaction
in risk. The optimum approach would be integration
of genetic and epidemiological research to investigate,
prospectively, the eﬀects of risk genes and gene–
environment interaction in prospective studies or
within high-risk groups.
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Controversies
GWAS eﬀorts have been subject to multiple criticisms,
both for the method generally and with respect to
psychiatric disorders. Criticism has been welcomed,
particularly when it is based on empirical data and not
opinion. One initial criticism – that GWAS will not
work in the sense of identifying any replicable as-
sociations – has been robustly disproved, as GWAS
clearly ‘works’ for a broad range of biomedical dis-
orders. The crucial question for our ﬁeld is whether
GWAS will ‘work’ for psychiatric disorders (as dis-
cussed above, there is positive evidence that it has).
Common criticisms of GWAS are listed below. All
have been articulated at length and strong counter-
arguments are available (see Table 1 for citations).
 Phenotype criticisms: the clinically derived DSM
and ICD systems are merely descriptive. The dis-
orders are too heterogeneous and imprecisely de-
ﬁned; that is investigating ‘schizophrenia ’ is like
studying ‘cancer ’ or ‘ fever ’.
 Genetic model criticisms. The vast majority of
GWAS use perhaps the simplest conceivable model,
a test for the additive eﬀect of a single, relatively
common SNP variant on the phenotype. Some have
argued that this model is completely wrong, that
risk for psychiatric disease is entirely something
else, that is risk is entirely due to rare variants, epi-
genetic modiﬁcations, etc.
 The ‘so what ’ criticism. Some have argued that
robust GWAS ﬁndings cannot contribute to in-
dividualized medicine and thus do not matter.
 An empirically based criticism of GWAS is that the
current genotyping technologies miss potentially
important genetic variation (e.g. a subset of com-
mon variants, a large proportion of rare variants,
non-SNP genetic variants such as insertion–deletion
polymorphisms, and are not optimal for CNV
detection).
Ethical, legal and social implications (ELSI)
Major scientiﬁc advances in the molecular genetic
understanding of psychiatric illness are associated
with important ethical issues that must be con-
sidered carefully. Although many issues in psychi-
atric genetics are no diﬀerent from those for other
complex disorders, this combination of genetics and
mental illness justiﬁably receives close scrutiny of
ethical and psychosocial issues. It is well known that
behavior genetics research has been misused in the
past, most notoriously to support Nazi claims of
racial superiority, which had an important role in
the Holocaust. It is therefore extremely important
that relevant issues are considered and debated as
early as possible and, where appropriate, ethical
guidance and legal frameworks put in place to pro-
tect individuals and society against potential misuse
of the new technologies and data. In recognition of
its major importance, ELSI was an integral compo-
nent of the Human Genome Project from its incep-
tion.
Key ethical issues under current debate include the
need for new approaches to informed consent for
large-scale genetic studies and consideration of the
legal issues relating to conﬁdentiality and use of gen-
etic data. For example, under what circumstances (if
any) might it be useful or appropriate to use genetic
data in a court case to support an argument about
responsibility for a behavior? Should insurance
companies or employers have access to genetic data
that inform risk of mental illness? How can we pre-
vent genetic results being used to reify racist, sexist
or other stigmatizing biases? Quite apart from these
potential non-medical uses of genetic data, there is the
important question of whether and when genetic tests
may be useful clinically : to help in conﬁrming diag-
nosis ; to direct management in a patient with signs of
illness ; or to predict risk in a person without signs of
illness. At present, risk variants have not been robustly
established that would provide clinically useful indi-
vidual predictive power and it may well be many
years in the future before this is possible. Nonetheless,
we need to think through the issues in advance of the
scientiﬁc and technical reality. It is highly desirable
that the clinical usefulness of any genetic test is
demonstrated before it is made widely available.
‘Direct to consumer’ genetic tests of spurious clinical
usefulness are already available commercially so there
is an urgent need to develop frameworks and guide-
lines for best practice.
In addition to the continuing public debate, con-
sultation and education on these issues, there is a need
for scrupulous integrity by scientists in the way they
present research ﬁndings. Reports should be appro-
priately cautious, balanced and free from ‘hype’,
‘ spin’ or commercial bias.
The exciting challenge for psychiatry in the coming
years is to ensure that a revolution in understanding of
the biology of mental illness is translated into a revol-
ution in clinical care. The important challenge for so-
ciety is to ensure that new knowledge and powerful
technologies are not misused.
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